HAP's Latest News

Pennsylvania (July 23, 2025)—Leaders from associations representing Pennsylvania health care providers and businesses released the following statement today about implications that the Pennsylvania Superior Court’s ruling in Hagans v. Hospital of the University of Pennsylvania will have on access to care and economic competitiveness across the commonwealth.

Fewer than half the commonwealth’s acute care hospitals are operating with margins necessary for long-term stability and more than a third continue to operate at a loss, according to data released today by the Pennsylvania Health Care Cost Containment Council (PHC4).

Pennsylvania’s hospitals and health systems face significant and persistent challenges that jeopardize communities’ access to health care, HAP and hospital leaders told a state Senate panel today.

The financial challenges of rural hospitals may have significant implications for health care access in rural areas, according to a new report by the Pennsylvania Health Care Cost Containment Council.

Hospitals continued to navigate challenging financial conditions as they approached the end of 2024.

As Pennsylvania ages and looks to revitalize its economy, hospitals are more important than ever to the health and vitality of communities. To meet these needs, the commonwealth’s hospitals have invested nearly $10 billion in strengthening the health of their communities, while supporting 1 in 9 jobs statewide and 19 percent of the commonwealth’s gross domestic product, an analysis released today by The Hospital and Healthsystem Association of Pennsylvania (HAP) indicates.

Across the nation, hospitals are continuing their financial progress in 2024, but recovery remains below the pre-pandemic baseline.

In a letter today, HAP and the Pennsylvania hospital community strongly opposed legislation that would create new regulatory burdens for hospitals while threatening access to care.

Johnson and Johnson (J&J) announced this week it was forgoing a controversial plan to offer rebates for certain 340B drugs instead of direct drug discounts.